Managing Overweight and Obesity in Adults to Reduce Cardiovascular Disease Risk

被引:49
作者
Ebbert, Jon O. [1 ]
Elrashidi, Muhamad Y. [1 ]
Jensen, Michael D. [2 ]
机构
[1] Mayo Clin, Div Primary Care Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Anti-obesity agents; Bariatric surgery; Cardiovascular diseases; Obesity; Overweight; Practice guidelines; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; INTENSIVE MEDICAL THERAPY; WEIGHT-LOSS; BARIATRIC SURGERY; CONTROLLED-TRIAL; LORCASERIN; TOPIRAMATE; AGONIST;
D O I
10.1007/s11883-014-0445-x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Obesity is a leading preventable cause of death and disability worldwide. Obesity increases the risk for clinically identifiable risk factors for cardiovascular disease (CVD) as well as a host of other metabolic, sleep, and orthopedic disorders. Coordinated and systematic interventions are needed to manage obesity and reduce these risks. The Obesity 2 Expert Panel updated the previous guidelines and produced the "Guideline for the Management of Overweight and Obesity in Adults." The Panel used data from publications from years 1999 to 2011 to address five critical questions, provide evidence statements, and recommend creation of a treatment algorithm to guide decision making about clinical care. The current review discusses the evidence statements pertaining to CVD risk in the assessment and management of patients who are overweight and obese. We summarize the FDA-approved medications for the treatment of overweight and obesity and their impact on CVD risk and risk factors, as well as ongoing clinical trials which will further inform clinical practice.
引用
收藏
页数:7
相关论文
共 29 条
[1]   Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) [J].
Allison, David B. ;
Gadde, Kishore M. ;
Garvey, William Timothy ;
Peterson, Craig A. ;
Schwiers, Michael L. ;
Najarian, Thomas ;
Tam, Peter Y. ;
Troupin, Barbara ;
Day, Wesley W. .
OBESITY, 2012, 20 (02) :330-342
[2]  
[Anonymous], 2013, OB OV
[3]  
[Anonymous], 2009, Global health risks: mortality and burden of disease attributable to selected major risks
[4]  
[Anonymous], 2011, FIND WHAT WORKS HLTH
[5]  
[Anonymous], 2011, GLOBAL STATUS REPORT
[6]   Predictors of weight loss in adults with topiramate-treated epilepsy [J].
Ben-Menachem, E ;
Axelsen, M ;
Johanson, EH ;
Stagge, A ;
Smith, U .
OBESITY RESEARCH, 2003, 11 (04) :556-562
[7]   A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial [J].
Fidler, Meredith C. ;
Sanchez, Matilde ;
Raether, Brian ;
Weissman, Neil J. ;
Smith, Steven R. ;
Shanahan, William R. ;
Anderson, Christen M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (10) :3067-3077
[8]  
Fleming JW, 2013, ANN PHARMACOTHER, V47, P1007, DOI [10.1345/aph.1R779, 10.1345/aph.1r779]
[9]   Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [J].
Gadde, Kishore M. ;
Allison, David B. ;
Ryan, Donna H. ;
Peterson, Craig A. ;
Troupin, Barbara ;
Schwiers, Michael L. ;
Day, Wesley W. .
LANCET, 2011, 377 (9774) :1341-1352
[10]   Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study [J].
Garvey, W. Timothy ;
Ryan, Donna H. ;
Look, Michelle ;
Gadde, Kishore M. ;
Allison, David B. ;
Peterson, Craig A. ;
Schwiers, Michael ;
Day, Wesley W. ;
Bowden, Charles H. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2012, 95 (02) :297-308